AI-generated · cited to primary sources · not investment advice
Divi's Lab. (532488) Nov 2025 Filing Analysis
Does management do what it says?
The company achieved a 16% increase in consolidated total income for the first half of FY26, maintaining its double-digit growth trajectory. (1 met, 1 missed, 3 revised across 5 tracked commitments)
“So, would the capex be higher than ₹2,000 crores for FY26? Nilima Prasad Divi: Yes, it would be higher in FY26.”
Management is hopeful that pricing pressure on generic molecules will stabilize in the next few quarters.
“But we are hopeful, like I explained in the last call, we're hopeful in the next few quarters, it may stabilize and things may come back to normal.”
See the full cited Management analysis of Divi's Lab.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.